APOL1 Gene Variants in African American Kidney Transplant Recipients
Stopped early
Conditions studied: Transplant;Failure,Kidney, Kidney Disease, Kidney Failure, Chronic
In brief
Aim 1: Determine if there is an association between the APOL1 risk variants and allograft survival and function in African Americans Aim 2: Determine if there is an association between the presence of APOL1 risk variants in an African American kidney transplant recipient and the risk of recurrent disease Aim 3: Investigate mechanisms of APOL1 associated kidney disease by prospectively following African American kidney transplant recipients throughout their clinical course.
Key facts
- Study ID
- NCT01442402
- Run by
- Brigham and Women's Hospital
- People needed
- 39
- Starts
- 2014-04-01
- Expected to finish
- 2014-04-01
- Last updated by the study team
- 2021-01-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- self-reported African American
- 18 years or older
- kidney transplant within 12 years
- Aim 2:
- Inclusion Criteria for patients with recurrent disease:
- self-reported African American
- 18 years or older
- kidney transplant within 12 years
- recurrent or de novo glomerular disease on allograft kidney biopsy
- Inclusion Criteria for control group:
- self-reported African American
- 18 years or older
- kidney transplant within 12 years
- end stage kidney disease due to glomerular nephritis, clinically diagnosed or by native kidney biopsy
- Exclusion Criteria for control group:
- clinical evidence of recurrent disease (presence of proteinuria, hematuria, Creatinine >2)
- Aim 3:
- Inclusion Criteria:
- self-reported African American
- 18 years or older
- scheduled living kidney transplant
Where it is running
- Brigham and Women's Hospital — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.